The bill, which faced significant pushback from drugmakers, industry lobby groups and patient advocacy groups, would require drugmakers to inform state officials and insurers of insulin price increases 90 days in advance. Drugmakers would also be required to publicly share annual list prices and profits for insulin, along with other currently private information.
Groups in opposition to the bill said the legislation did not account for rebates paid to middlemen and unfairly targets diabetes patients.
Mr. Sandoval said the bill contained well-intentioned provisions to increase access to affordable healthcare, but also carried potentially harmful consequences for state residents, including “the possibility that access to critical care will become more expensive, more restricted and less equitable,” reports Las Vegas Review Journal.
More articles on supply chain:
Premier: 9 policy recommendations to fix high drug costs
6 FDA decisions to keep an eye on in June
Eli Lilly CFO to retire at year-end
